Abstract
During the last decade, there has been an increasing use of a placebo run-in period prior to randomization to active treatments, or placebo in randomized controlled trials aimed at establishing acute phase antidepressant drug efficacy in patients with major depression. This procedure is thought to reduce response rates to placebo treatment after randomization, thereby increasing the drug-placebo difference. Metaanalyses of 101 studies reveal that a placebo run-in does not (1) lower the placebo response rate, (2) increase the drug-placebo difference, or (3) affect the drug response rate post-randomization in either inpatients or outpatients for any antidepressant drug group. If there is a post-randomization placebo treatment cell, drug response rates are unchanged or are slightly lower than if there is no placebo treatment cell for outpatients. These results suggest that a pill placebo run-in provides no advantage in acute phase efficacy trials.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Additional information
Address reprint requests to: Madhukar H. Trivedi, M.D., MHCRC at St. Paul POB I, 5959 Harry Hines Blvd., Suite 600, Dallas, Texas 75235-9101.
Rights and permissions
About this article
Cite this article
Trivedi, M., Rush, J. Does a Placebo Run-In or a Placebo Treatment Cell Affect the Efficacy of Antidepressant Medications?. Neuropsychopharmacol 11, 33–43 (1994). https://doi.org/10.1038/npp.1994.63
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/npp.1994.63
Keywords
This article is cited by
-
How should we design future mechanistic and/or efficacy clinical trials?
Neuropsychopharmacology (2024)
-
Possible Strategies to Mitigate Placebo or Vehicle Response in Dry Eye Disease Trials: A Narrative Review
Ophthalmology and Therapy (2023)
-
Mechanisms of the placebo effect in pain and psychiatric disorders
The Pharmacogenomics Journal (2016)
-
Using Placebo Response to Pain as a Predictor of Placebo Response in Mood Disorders
Current Behavioral Neuroscience Reports (2016)
-
A Novel Methodology to Estimate the Treatment Effect in Presence of Highly Variable Placebo Response
Neuropsychopharmacology (2015)